EUVIMEDEUVIMED entdecken
Crossref

Safety and Efficacy of Khamira Gawzaban Sada (KGS) in Mild Cognitive Impairment: A Pilot Open-Label Clinical Trial

Humaira Bano, Nikhat Shaikh, Shah Alam, Arjumand Shah, Mohammed Sheeraz, Irfan Ahmed, MD Manzar Alam

Acta Pharma Reports · 11.03.2022 · 1 (1) · 2-4

DOI: 10.51470/apr.2022.01.01.02 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Acta Pharma Reports, online erschienen am 19.03.2022. Verfasst von Humaira Bano und 6 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Mild cognitive impairment (MCI), termed Zu’f al-Dimagh in Unani medicine, is a clinically significant precursor to dementia with limited pharmacological options.

Objective

To evaluate the efficacy and safety of Khamira Gawzaban Sada (KGS), a standardized Pharmacopoeial Unani compound, in patients with MCI.

Methods

An open-label, single-arm pilot trial enrolled 100 participants (screened n=150) with MMSE scores of 10–23. KGS was administered orally at 10 g/day for six weeks. Primary outcome was change in MMSE score; secondary outcome was patient-reported Quality of Life (QoL). Safety was monitored through adverse event surveillance, laboratory parameters, and vital signs at baseline, Week 2, Week 4, and Week 6.

Results

Mean MMSE scores improved significantly from 16.2 (±2.8) at baseline to 22.4 (±1.9) at Week 6 (p

Zitieren

APA

Bano, H., Shaikh, N., Alam, S., Shah, A., Sheeraz, M., Ahmed, I., & Alam, M. M. (2022). Safety and Efficacy of Khamira Gawzaban Sada (KGS) in Mild Cognitive Impairment: A Pilot Open-Label Clinical Trial. Acta Pharma Reports, 1(1), 2-4. https://doi.org/10.51470/apr.2022.01.01.02

Vancouver

Bano H, Shaikh N, Alam S, Shah A, Sheeraz M, Ahmed I, et al. Safety and Efficacy of Khamira Gawzaban Sada (KGS) in Mild Cognitive Impairment: A Pilot Open-Label Clinical Trial. Acta Pharma Reports. 2022;1(1):2-4. doi:10.51470/apr.2022.01.01.02

BibTeX
@article{Bano2022,
  author = {Bano, Humaira and Shaikh, Nikhat and Alam, Shah and Shah, Arjumand and Sheeraz, Mohammed and Ahmed, Irfan and Alam, MD Manzar},
  title = {Safety and Efficacy of Khamira Gawzaban Sada (KGS) in Mild Cognitive Impairment: A Pilot Open-Label Clinical Trial},
  journal = {Acta Pharma Reports},
  year = {2022},
  volume = {1},
  number = {1},
  pages = {2--4},
  doi = {10.51470/apr.2022.01.01.02}
}
Kostenlos starten →